healthtech bpc 157 BPC-157 – Mark Hyman, MD BPC-157 Injectable Peptide for Healing
Description
This triple mechanism distinguishes it from dual-agonist peptides like tirzepatide (GLP-1/GIP) and single-agonist compounds like semaglutide (GLP-1 only), making it the most broadly acting incretin-class compound currently under clinical investigation
once you have the vial and supplies, each injections cost lower overall, though there is an upfront cost for the consultation
10.1128/AEM.01931-07 151 KaratzasK
No longterm human trials exist
Research Background The foundational research on BPC-157 was published by Sikiric et al
